MediciNova, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $68.2M
- Price
- $1.39
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.46%
- Volume
- 26.1K
About
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.
Quick stats
Shares outstanding49.0M
Computed float40.3M
Float / shares82.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001226616
Websitehttps://www.medicinova.com
AI Summary
AI-generated1/8
standardbullishclinical trial
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
MediciNova announced it has achieved the target enrollment of 200 patients in the SEANOBI-ALS study, an NIH-funded expanded access program evaluating MN-166 (ibudilast) in ALS patients.
The program is designed to provide access to individuals not eligible for randomized trials, with final patient follow-ups projected to conclude in early 2027 to support data analysis and scientific publications.
MN-166 holds Fast Track and Orphan Drug designations for ALS and remains the company's lead asset, currently in Phase 2b/3 development for the indication.